| 摘要 |
PROBLEM TO BE SOLVED: To provide methods of assessing the effect, efficacy, safety, and/or dosing of therapeutic agents (or drug), such as integrin beta7 antagonists, for the treatment of gastrointestinal tract inflammatory disorders.SOLUTION: The present invention relates to a method of use of biomarkers for evaluating the therapy of gastrointestinal tract inflammatory disorders with beta7 antagonist, the methods using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal tract inflammatory disorders.SELECTED DRAWING: None |
